COMBINED INHIBITION OF PD-1/PD-L1, TGFB AND DNA-PK FOR THE TREATMENT OF CANCER

摘要

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 axis binding antagonist, a TGFβ inhibitor and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 expression.